TY  - JOUR
AU  - Flores-Burgess, Antonio
AU  - Millón, Carmelo
AU  - Gago, Belén
AU  - Narváez, Manuel
AU  - Borroto-Escuela, Dasiel O
AU  - Mengod, Guadalupe
AU  - Narváez, José Angel
AU  - Fuxe, Kjell
AU  - Santín, Luis
AU  - Díaz-Cabiale, Zaida
PY  - 2017
DO  - 10.1016/j.neuropharm.2017.03.010
UR  - http://hdl.handle.net/10668/10958
T2  - Neuropharmacology
AB  - The pharmacological treatment of major depression is mainly based on drugs elevating serotonergic (5-HT) activity. Specifically, selective 5-HT reuptake inhibitors, including Fluoxetine (FLX), are the most commonly used for treatment of major...
LA  - en
KW  - 5-HT1A receptor
KW  - Depression
KW  - Fluoxetine
KW  - Galanin(1-15)
KW  - Animals
KW  - Antidepressive Agents
KW  - Autoradiography
KW  - Cyclohexanes
KW  - Depression
KW  - Disease Models, Animal
KW  - Dose-Response Relationship, Drug
KW  - Drug Delivery Systems
KW  - Drug Therapy, Combination
KW  - Fluoxetine
KW  - Galanin
KW  - Hippocampus
KW  - Immobility Response, Tonic
KW  - Male
KW  - Peptide Fragments
KW  - Piperazines
KW  - RNA, Small Interfering
KW  - Rats
KW  - Rats, Sprague-Dawley
KW  - Receptor, Galanin, Type 1
KW  - Receptor, Galanin, Type 2
KW  - Statistics, Nonparametric
KW  - Swimming
TI  - Galanin (1-15) enhancement of the behavioral effects of Fluoxetine in the forced swimming test gives a new therapeutic strategy against depression.
TY  - research article
VL  - 118
ER  -